» Articles » PMID: 31505020

Serum Cytokines Elevated During Gluten-mediated Cytokine Release in Coeliac Disease

Overview
Date 2019 Sep 11
PMID 31505020
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Cytokines have been extensively studied in coeliac disease, but cytokine release related to exposure to gluten and associated symptoms has only recently been described. Prominent, early elevations in serum interleukin (IL)-2 after gluten support a central role for T cell activation in the clinical reactions to gluten in coeliac disease. The aim of this study was to establish a quantitative hierarchy of serum cytokines and their relation to symptoms in patients with coeliac disease during gluten-mediated cytokine release reactions. Sera were analyzed from coeliac disease patients on a gluten free-diet (n = 25) and from a parallel cohort of healthy volunteers (n = 25) who underwent an unmasked gluten challenge. Sera were collected at baseline and 2, 4 and 6 h after consuming 10 g vital wheat gluten flour; 187 cytokines were assessed. Confirmatory analyses were performed by high-sensitivity electrochemiluminescence immunoassay. Cytokine elevations were correlated with symptoms. Cytokine release following gluten challenge in coeliac disease patients included significant elevations of IL-2, chemokine (C-C motif) ligand 20 (CCL20), IL-6, chemokine (C-X-C motif) ligand (CXCL)9, CXCL8, interferon (IFN)-γ, IL-10, IL-22, IL-17A, tumour necrosis factor (TNF)-α, CCL2 and amphiregulin. IL-2 and IL-17A were earliest to rise. Peak levels of cytokines were generally at 4 h. IL-2 increased most (median 57-fold), then CCL20 (median 10-fold). Cytokine changes were strongly correlated with one another, and the most severely symptomatic patients had the highest elevations. Early elevations of IL-2, IL-17A, IL-22 and IFN-γ after gluten in patients with coeliac disease implicates rapidly activated T cells as their probable source. Cytokine release after gluten could aid in monitoring experimental treatments and support diagnosis.

Citing Articles

Celiac Disease and Gluten Cross-Contact: How Much is too Much?.

Stout J, Austin K, Bonnes S, Dubroff J, Muratore A Curr Nutr Rep. 2025; 14(1):41.

PMID: 40038204 DOI: 10.1007/s13668-025-00621-8.


InTiCAR: Network-based identification of significant inter-tissue communicators for autoimmune diseases.

Kim K, Han M, Lee D Comput Struct Biotechnol J. 2025; 27:333-345.

PMID: 39897058 PMC: 11782887. DOI: 10.1016/j.csbj.2025.01.003.


Circulating MicroRNAs and Cytokines Associated with Celiac Disease.

Hammad D, Muslim Alameedy F Middle East J Dig Dis. 2024; 16(3):185-192.

PMID: 39386332 PMC: 11459281. DOI: 10.34172/mejdd.2024.388.


The role of IL-37 in gastrointestinal diseases.

Wang Q, Zhang G, An C, Hambly B, Bao S Front Immunol. 2024; 15:1431495.

PMID: 39206201 PMC: 11349528. DOI: 10.3389/fimmu.2024.1431495.


The Role of Viruses in the Pathogenesis of Immune-Mediated Gastro-Intestinal Diseases.

Bernardi F, Ungaro F, DAmico F, Zilli A, Parigi T, Massimino L Int J Mol Sci. 2024; 25(15).

PMID: 39125870 PMC: 11313478. DOI: 10.3390/ijms25158301.


References
1.
Yao W, Ba Q, Li X, Li H, Zhang S, Yuan Y . A Natural CCR2 Antagonist Relieves Tumor-associated Macrophage-mediated Immunosuppression to Produce a Therapeutic Effect for Liver Cancer. EBioMedicine. 2017; 22:58-67. PMC: 5552238. DOI: 10.1016/j.ebiom.2017.07.014. View

2.
Lundin K, Scott H, Hansen T, Paulsen G, Halstensen T, Fausa O . Gliadin-specific, HLA-DQ(alpha 1*0501,beta 1*0201) restricted T cells isolated from the small intestinal mucosa of celiac disease patients. J Exp Med. 1993; 178(1):187-96. PMC: 2191064. DOI: 10.1084/jem.178.1.187. View

3.
Fina D, Sarra M, Caruso R, Del Vecchio Blanco G, Pallone F, MacDonald T . Interleukin 21 contributes to the mucosal T helper cell type 1 response in coeliac disease. Gut. 2007; 57(7):887-92. DOI: 10.1136/gut.2007.129882. View

4.
Nilsen E, Lundin K, Krajci P, Scott H, Sollid L, Brandtzaeg P . Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon gamma. Gut. 1995; 37(6):766-76. PMC: 1382937. DOI: 10.1136/gut.37.6.766. View

5.
Suntharalingam G, Perry M, Ward S, Brett S, Castello-Cortes A, Brunner M . Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006; 355(10):1018-28. DOI: 10.1056/NEJMoa063842. View